April 23rd 2025
Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected in 2026, and if approved, would be the second cell therapy for type 1 diabetes.
Unintended Effects of Caps on Insulin Out-of-Pocket Costs
March 28th 2024People with higher incomes and those in health plans with health savings accounts benefit more than others, according to research results published this week in the Annals of Internal Medicine. The research also showed no increase in insulin use,
Read More